To include your compound in the COVID-19 Resource Center, submit it here.

From Scotland to MaRS

GlaxoSmithKline plc has begun ramping up its collaborations with academia through two programs that will identify and fast-track the development of academic research with commercial potential. On the one hand, it is forging alliances with individual researchers through its Discovery Partnerships with Academia program, which will reward successful researchers all the way from bench to bedside. On the other hand, the pharma will help Toronto-based technology transfer organization MaRS Innovation identify its most commercially viable research in exchange for rights of first refusal.

Through Discovery Partnerships with Academia (DPAc), the pharma will partner with about 10 individual academic researchers over the next year to develop early stage projects and thus give these academics a more expedient alternative route to developing a medicine besides starting a company, said Duncan Holmes, head of DPAc at GSK.

GSK announced its first DPAc alliance

Read the full 1383 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers